北京德恒（杭州）律师事务所 关于迪安诊断技术集团股份有限公司 2025年第一次临时股东大会的 法律意见书 杭州市上城区新业路 200 号华峰国际商务大厦 10-11 楼 邮编：310016 电话：(+86)0571-86508080 传真：(+86)0571-87357755 北京德恒（杭州）律师事务所 关于迪安诊断技术集团股份有限公司 2025年第一次临时股东大会的法律意见书 北京德恒（杭州）律师事务所 德恒【杭】书（2025）第 12073 号 致：迪安诊断技术集团股份有限公司 迪安诊断技术集团股份有限公司（下称"公司"）2025 年第一次临时股东 大会（下称"本次股东大会"）于 2025 年 12 月 31 日（星期三）14:30 在杭州市 西湖区三墩镇金蓬街 329 号召开。北京德恒（杭州）律师事务所（下称"本所"） 受公司委托，指派本所律师出席本次股东大会。根据《中华人民共和国公司法》 （下称"《公司法》"）《上市公司股东大会规则》（下称"《股东大会规则》"） 等相关法律、法规、规范性文件以及《迪安诊断技术集团股份有限公司章程》（下 称"《公司章程》"）和《迪安诊断技术集团股份有限公司股东大会议事规 ...

证券代码：300244 证券简称：迪安诊断 公告编号：2025-044 迪安诊断技术集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召开时间 （1）现场会议时间：2025 年 12 月 31 日（星期三）14:30。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 12 月 31 日 9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交 易所互联网投票系统的具体时间为：2025 年 12 月 31 日 9:15-15:00。 2、会议召开地点：杭州市西湖区三墩镇金蓬街 329 号。 3、会议召开方式：本次股东大会以现场投票与网络投票相结合的方式召开。 4、会议召集人：公司董事会。 5、会议主持人：陈海斌先生。 6、会议出席情况： 二、议案审议情况 本次股东大会采取现场记名投票与网络投票表决相结合的方式 ...

【文/王力 编辑/周远方】 2025年末，全国流感疫情持续处于高流行水平。据国家疾控中心监测数据，当前主导毒株以甲型H3N2为主，该毒株传播力较强，且人群普遍易感。随着元 旦假期临近，春运序幕即将拉开，大规模人口流动将显著增加病毒传播机会，医疗系统和药品供应体系面临阶段性压力测试。 从终端市场反馈看，抗病毒药物和呼吸道对症药品需求集中释放。阿里健康平台数据显示，近两周流感相关药品购买人数环比增长超过500%；美团买药平 台清热解毒、止咳化痰类中成药订单量增幅突破100%；线下药店相关品类补货频率较平日提升2至3倍。与此同时，京东到家呼吸道病原检测订单量环比增 长66%，专业上门检测服务需求接近翻倍，反映出消费者对精准诊疗的认知提升。 面对这一公共卫生挑战，医药产业链各环节积极响应。从上游疫苗企业加速批签发，到中游制药企业扩大产能，再到下游流通企业保障配送时效，一条覆盖 预防、诊断、治疗的完整链条正在高效运转。值得关注的是，本轮疫情中化学药与中成药呈现协同发力的态势，市场格局较以往有所变化。 产业链协同响应，构建多层次供应保障 流感防控是一项系统工程，需要疫苗预防、快速诊断、药物治疗等多个环节的有效衔接。本轮疫 ...

Core Viewpoint - The medical device sector is experiencing significant growth and investment opportunities, driven by recent regulatory approvals and technological advancements in brain-computer interface (BCI) technology [3][4][5]. Group 1: Market Performance - The medical device index ETF (159898) saw a 1.11% increase, with approximately 20 million yuan net inflow during trading [1]. - Key stocks in the medical device sector, such as Yirui Technology and Furu Medical, reported gains of 4.58% and 6.44% respectively, indicating strong market performance [1]. Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) approved two high-value medical devices, enhancing clinical applications and technological development in the industry [3]. - Recent policies from major cities like Shanghai and Beijing aim to support the medical device industry, focusing on regulatory reforms and innovation [5]. Group 3: Technological Advancements - China has made significant progress in invasive brain-computer interface technology, becoming the second country after the U.S. to enter clinical trials [3]. - The global brain-computer interface market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate of 17.35% [4]. Group 4: Investment Opportunities - Analysts suggest that the medical device sector may replicate the successful path of innovative pharmaceuticals, with a focus on innovation driving industry growth and global competitiveness [5]. - The medical device index ETF (159898) tracks a diverse range of leading companies in the sector, primarily focusing on A-share medical devices [7].

Core Viewpoint - The Biotech Economy Index (970038) closed at 2120.29 points, down 0.12%, with a trading volume of 13.62 billion yuan and a turnover rate of 1.11% [1] Group 1: Index Performance - On the day, 16 stocks in the Biotech Economy Index rose, with Deep Technology leading at a 2.83% increase, while 30 stocks fell, with Dean Diagnostics leading the decline at 2.96% [1] - The net outflow of main funds from the Biotech Economy Index stocks totaled 640 million yuan, while retail investors saw a net inflow of 454 million yuan [1] Group 2: Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (sz300760) with a weight of 12.66% and a market cap of 242.125 billion yuan [1] - Shizhu Aoshi (sz002252) with a weight of 4.95% and a market cap of 42.549 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 4.56% and a market cap of 38.832 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.17% and a market cap of 51.585 billion yuan [1] - Taige Pharmaceutical (sz300347) with a weight of 4.10% and a market cap of 44.119 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.87% and a market cap of 270.899 billion yuan [1] - Deep Technology (sz000021) with a weight of 3.86% and a market cap of 38.318 billion yuan [1] - Jiao Yue Medical (sz002223) with a weight of 3.22% and a market cap of 37.854 billion yuan [1] - Aimeike (sz300896) with a weight of 3.04% and a market cap of 43.694 billion yuan [1] - Watson Bio (sz300142) with a weight of 3.00% and a market cap of 17.833 billion yuan [1] Group 3: Fund Flow Details - The fund flow details indicate that Deep Technology had a main fund net inflow of 151 million yuan, while retail investors had a net outflow of 91.497 million yuan [2] - Kanglong Chemical experienced a main fund net inflow of 17.121 million yuan, with retail investors seeing a net inflow of 1.917 million yuan [2] - The Biotech Economy Index constituents underwent adjustments, adding 9 stocks and removing 9 stocks [2][3]

Investment Rating - The report maintains an "Overweight" rating for the industry [5] Core Insights - The pharmaceutical sector is experiencing a phase of oscillation and differentiation, with a recommendation to seize thematic rotation and bottom adjustment opportunities, particularly in the innovative drug supply chain and AI+ sectors [6][13] - The long-term growth driver for the pharmaceutical sector is technological innovation, with key focuses on "continuation of policy benefits," "breakthroughs in frontier technologies," and "international BD transactions" [6][13] - The report highlights the potential of new generation CTLA-4 therapies that address toxicity issues, thereby unlocking market potential [7] Summary by Sections Industry Overview - The pharmaceutical industry comprises 499 listed companies with a total market value of 71,291.29 billion [2] - The industry is currently valued at 25.8 times PE based on 2025 earnings forecasts, with a premium of 10.2% over the overall A-share market [22] Market Dynamics - The report notes a 14.49% return for the pharmaceutical sector since the beginning of 2025, underperforming the CSI 300 index by 1.60 percentage points [19] - Recent market movements show a decline in the pharmaceutical sector, with specific segments like pharmaceutical commerce and medical devices showing positive growth [19][6] Key Recommendations - Focus on companies involved in innovative drug development and AI applications, such as 恒瑞医药 (Hengrui Medicine), 中国生物制药 (China National Pharmaceutical Group), and 康方生物 (Kangfang Biopharma) [6][13] - The report emphasizes the importance of addressing clinical pain points and enhancing safety in new generation immuno-oncology drugs [7] Notable Companies - The report recommends several companies for investment, including 康方生物 (Kangfang Biopharma), 药明合联 (WuXi AppTec), and 泰格医药 (Tigermed) [7][30] - It highlights the performance of specific stocks, noting that the average decline for 中泰医药 (Zhongtai Medicine) was 2.51% this month, while it outperformed the industry by 0.68% this week [29][30]

Core Viewpoint - The company Di'an Diagnostics has announced the acquisition of a patent for a colorectal cancer detection biomarker, focusing on non-invasive urine sample testing, with commercialization currently in the early verification and technical assessment stage [1] Group 1: Patent and Technology - The patent titled "A Biomarker for Colorectal Cancer Detection and Its Application" was granted to Kailai Pu on October 3, 2025 [1] - The core technology involves a set of novel biomarkers for colorectal cancer detection, emphasizing convenience, non-invasiveness, and efficiency [1] Group 2: Commercialization Process - The company acknowledges that transitioning from patent authorization to a mature diagnostic product requires rigorous clinical validation, product development, and registration processes [1] - The company is committed to advancing the market application of this technology with a proactive and cautious approach [1]

Core Viewpoint - The company emphasizes that the shareholding reform is a crucial step for enterprises to enter the capital market [1] Group 1: Company Developments - The company's subsidiary, Kailai Pu, completed its transformation from a limited liability company to a joint-stock company in November 2023 [1] - Kailai Pu is currently in the ongoing preparation for its listing process [1] - The company will fulfill its information disclosure obligations in accordance with relevant regulations as progress on related matters becomes clear [1]

Group 1 - The core index of the biotechnology sector (970038) closed at 2106.64 points, with an increase of 0.41% and a trading volume of 13.689 billion yuan, resulting in a turnover rate of 1.1% [1] - Among the constituent stocks, 29 companies experienced an increase, with Dean Diagnostics leading the rise at 8.65%, while 18 companies saw a decline, with Yingke Medical leading the drop at 1.59% [1] Group 2 - The net inflow of main funds into the biotechnology index constituents totaled 105 million yuan, while speculative funds saw a net outflow of 259 million yuan, and retail investors had a net inflow of 155 million yuan [2] - In the past 10 days, the biotechnology index constituents underwent adjustments, adding 9 new stocks and removing 9 stocks [2]

Core Viewpoint - The DRG/DIP concept sector experienced a significant increase of 3.87%, leading the market in terms of growth, with notable performances from stocks such as Jiahe Meikang and Saily Medical, which reached their daily limit up [1][2]. Group 1: Market Performance - The DRG/DIP concept sector had 19 stocks rising, with Jiahe Meikang hitting a 20% limit up, followed by Saily Medical at limit up, and other notable gainers including Weining Health, Dian Diagnostics, and Sichuang Medical, which rose by 11.11%, 8.65%, and 5.77% respectively [1]. - The sector saw a net inflow of 737 million yuan from main funds, with 17 stocks receiving net inflows, and 11 stocks exceeding 10 million yuan in net inflow [2]. - The top net inflow stock was Weining Health, attracting 347 million yuan, followed by Saily Medical, Rongke Technology, and Jiayuan Technology with net inflows of 166 million yuan, 83.78 million yuan, and 44.88 million yuan respectively [2]. Group 2: Fund Flow Ratios - Saily Medical, Digital Certification, and Weining Health had the highest net inflow ratios, with rates of 29.65%, 13.45%, and 12.89% respectively [3]. - The top stocks in the DRG/DIP concept based on net inflow include Weining Health with a daily increase of 11.11% and a turnover rate of 15.28%, and Saily Medical with a 9.99% increase and a turnover rate of 12.43% [3][4]. - Other notable stocks include Rongke Technology, Jiayuan Technology, and Jiahe Meikang, which also showed positive performance with increases of 0.90%, 3.27%, and 20.01% respectively [4].